• SKIP TO CONTENT
  • SKIP NAVIGATION
  • Patient Resources
    • COVID-19 Patient Resource Center
    • Clinical Trials
    • Search Clinical Trials
    • Patient Notification System
    • What is Clinical Research?
    • Volunteering for a Clinical Trial
    • Understanding Informed Consent
    • Useful Resources
    • FDA Approved Drugs
  • Professional Resources
    • Research Center Profiles
    • Clinical Trial Listings
    • Market Research
    • FDA Approved Drugs
    • Training Guides
    • Books
    • Events
    • Newsletters
    • JobWatch
    • White Papers
    • Patient Education
    • SOPs
    • eCFR and Guidances
  • White Papers
  • Trial Listings
  • Advertise
  • COVID-19
  • iConnect
  • Sign In
  • Create Account
  • Sign Out
  • My Account
Home » Directories » FDA Approved Drugs » Fetzima (levomilnacipran)

AND
  • A
  • B
  • C
  • D
  • E
  • F
  • G
  • H
  • I
  • J
  • K
  • L
  • M
  • N
  • O
  • P
  • Q
  • R
  • S
  • T
  • U
  • V
  • W
  • X
  • Y
  • Z

Fetzima (levomilnacipran)

  • Profile

Profile

Contact Information

Currently Enrolling Trials

    Show More

    General Information

    Fetzima (levomilnacipran) is an extended release selective norepinephrine and serotonin reuptake inhibitor.

    Fetzima is specifically indicated for the treatment of Major Depressive Disorder.

    Fetzima is supplied as a capsule for oral administration. The recommended dose is 40 mg to 120 mg once daily with or without food. Initiate dose at 20 mg once daily for 2 days and then increase to 40 mg once daily. The dose should be increased in increments of 40 mg at intervals of 2 or more days. The maximum recommended dose is 120 mg once daily. The capsules should be swallowed whole.

    Clinical Results

    FDA Approval
    The FDA approval of Fetzima was based on three 8-week randomized, double-blind, placebo-controlled studies (at doses 40­120 mg once daily) in adult (18 - 78 years of age) outpatients who met the Diagnostic and Statistical Manual of Mental Disorders (DSM-IV-TR) criteria for MDD. Two of the studies were fixed dose (Study 1 and Study 2) and one study was flexible dose (Study 3). In Study 1, patients received 40 mg, 80 mg or 120 mg of Fetzima once daily, or placebo. In Study 2, patients received either 40 mg or 80 mg of Fetzima once daily, or placebo. In the flexible-dose study (Study 3), patients received 40 to 120 mg of Fetzima once daily, or placebo. In all three studies, Fetzima demonstrated superiority over placebo in the improvement of depressive symptoms as measured by the Montgomery-Asberg Depression Rating Scale (MADRS) total score. Fetzima also demonstrated superiority over placebo as measured by improvement in the Sheehan Disability Scale (SDS) functional impairment total score.

    Side Effects

    Adverse events associated with the use of Fetzima may include, but are not limited to, the following:

    • nausea
    • constipation
    • hyperhidrosis
    • heart rate increase
    • erectile dysfunction
    • tachycardia
    • vomiting
    • palpitations

    Mechanism of Action

    Fetzima (levomilnacipran) is an extended release selective norepinephrine and serotonin reuptake inhibitor. The exact mechanism of the antidepressant action of levomilnacipran is unknown, but is thought to be related to the potentiation of serotonin and norepinephrine in the central nervous system, through inhibition of reuptake at serotonin and norepinephrine transporters. Non-clinical studies have shown that levomilnacipran is a potent and selective serotonin and norepinephrine reuptake inhibitor (SNRI).

    Literature References

    Asnis GM, Bose A, Gommoll CP, Chen C, Greenberg WM Efficacy and safety of levomilnacipran sustained release 40 mg, 80 mg, or 120 mg in major depressive disorder: a phase 3, randomized, double-blind, placebo-controlled study. Journal of Clinical Psychiatry 2013 Mar;74(3):242-8

    Montgomery SA, Mansuy L, Ruth A, Bose A, Li H, Li D Efficacy and safety of levomilnacipran sustained release in moderate to severe major depressive disorder: a randomized, double-blind, placebo-controlled, proof-of-concept study. Journal of Clinical Psychiatry 2013 Apr;74(4):363-9

    Additional Information

    For additional information regarding Fetzima or major depressive disorder, please visit the Fetzima web page.

    Approval Date: 2013-07-01
    Company Name: Forest Laboratories
    Back to Listings

    Upcoming Events

    • 26Jan

      Reducing Complexity in Starting Clinical Trials – More Patients, Faster Startup

    • 27Jan

      Medical Device Clinical Trials in China: Latest Regulatory Developments

    • 11Feb

      Lab X.0: Addressing Quality and Compliance Challenges in Laboratory Operations in the COVID-19 All-Digital Era

    • 23Mar

      Data Integrity for GCP Professionals: Core Requirements, Expectations and Challenges

    • 26Apr

      MAGI's Clinical Research vConference — Spring 2021

    Featured Products

    • Regenerative Medicine – Steps to Accelerate Development : PDF

      Regenerative Medicine: Steps to Accelerate Development

    • Clinical Trial Agreements — A Guide to Key Words and Phrases : PDF

      Clinical Trial Agreements: A Guide to Key Words and Phrases

    Featured Stories

    • TechInnovation-360x240.png

      Pace of Technology Innovation in Trials Could Slow After Pandemic Eases

    • AskTheExperts-360x240.png

      Ask the Experts: Certifying and Maintaining Copies of Original Source Documents

    • Resources-360x240.png

      Trial Complexity, Endpoints Continue to Increase, Stretching Site Resources

    • FocusinRed-360x240.png

      Return to Focus on Risk Management Postpandemic Could Prove Challenging to Sites

    Standard Operating Procedures for Risk-Based Monitoring of Clinical Trials

    The information you need to adapt your monitoring plan to changing times.

    Learn More Here
    • About Us
    • Contact Us
    • Privacy Policy
    • Do Not Sell My Personal Information

    Footer Logo

    300 N. Washington St., Suite 200, Falls Church, VA 22046, USA

    Phone 617.948.5100 – Toll free 866.219.3440

    Copyright © 2021. All Rights Reserved. Design, CMS, Hosting & Web Development :: ePublishing